每周股票复盘：奥精医疗（688613）股东减持完成，2024年净利亏损超1200万

Core Points - Aojing Medical (688613) closed at 18.93 yuan on May 30, 2025, up 9.55% from the previous week [1] - The company's total market capitalization is 2.594 billion yuan, ranking 108th in the medical device sector and 4464th in the A-share market [1] Shareholder Changes - BioVeda China RMB Investment Limited reduced its holdings by 345,087 shares, accounting for 0.25% of the total share capital [1][3] - Prior to the reduction, BioVeda held 7,584,445 shares, representing 5.6% of Aojing Medical's total shares [1] - As of May 25, 2025, BioVeda's remaining shares are 7,239,358, with a holding percentage of 5.28% [1] Company Financials - Aojing Medical's 2024 annual report shows a revenue of 206,033,014.77 yuan, a decrease of 9.03% year-on-year [2] - The net profit attributable to shareholders was -12,662,162.69 yuan, a decline of 123.35% compared to the previous year [2] - The net assets attributable to shareholders increased by 1.50% to 1.402 billion yuan, while total assets grew by 0.85% to 1.539 billion yuan [2] - The company confirmed that sales to a single customer exceeded 50% of total sales during the reporting period, indicating a significant reliance on a few customers [2]